<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-11109-2012025 - 2S5KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Why is antiretroviral therapy not always effective?</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Current antiretroviral therapy is a giant improvement compared with previous treatments. Nevertheless, statistics show that for one quarter of HIV treatment patients, the immune system does not recover. AMC researcher, Aleksander Pasternak, aims to identify why these patients&#x2019; blood viral load does not drop and their antibody levels do not return to normal. To do this, he will determine whether those patients who do not respond well to HIV treatment have any specific immune system disorders.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">Current antiretroviral therapy is a giant improvement compared with previous treatments. Nevertheless, statistics show that for one quarter of HIV treatment patients, the immune system does not recover.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">This research project will be the first to investigate in parallel a significant number of virological, immunological, and genetic factors in relation to IF. In particular, virus production and the size of viral reservoir will be assessed using our innovative seminested real-time PCR assays. Both a retrospective case-control study including significant numbers of patients, and a prospective study of patients followed from the start of ART will be performed. Taken together, these two studies will allow comparing different virus and host biomarkers between immunological responders and nonresponders, investigating the dynamics and mutual correlation of these biomarkers, and &#x2013; most importantly &#x2013; determining the predictive value of these biomarkers for IF.  
The researchquestions are: 
1. Does virus production in patients on ART correlate with IF? 
2. Is IF associated with co-infection with other pathogens and microbial translocation? 
3. Which of the aforementioned influences are mediated through increased T-cell activation and apoptosis? 
4. Which other immunological biomarkers correlate with IF? 
5. Does host genetics determine IF? 
6. Does decreased thymic output influence IF? 
7. Do the levels and longitudinal trends of immunological and virological biomarkers correlate with each other? 
8. Which of the aforementioned host and viral factors are predictive for IF, in a prospectively followed patient cohort? 
 
The ultimate goal of this research is personalized etiological diagnosis and treatment for every individual with an incomplete therapy response. This is of benefit of the individual patient but may also prevent transmission of HIV</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">scientific community</narrative>
  </description>
  <participating-org ref="NL-KVK-34362777" role="4" type="80">
   <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2013-02-11" type="2"></activity-date>
  <activity-date iso-date="2020-11-01" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C70" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2013-02-11"></period-start>
   <period-end iso-date="2020-11-01"></period-end>
   <value currency="EUR" value-date="2013-02-11">250000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">201000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2012025, CG651011</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org receiver-activity-id="NL-KVK-34362777-P-11109" ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">201000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2012025, CG651011</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org receiver-activity-id="NL-KVK-34362777-P-11109" ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-06-13"></transaction-date>
   <value currency="EUR" value-date="2021-06-13">49000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org receiver-activity-id="NL-KVK-34362777-P-11109" ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-06-14"></transaction-date>
   <value currency="EUR" value-date="2021-06-14">49000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org receiver-activity-id="NL-KVK-34362777-P-11109" ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-17208-2S4" type="1"></related-activity>
 </iati-activity>
</iati-activities>
